Vir Biotechnology, Inc. (VIR)
$30.14
Rating:
Recommendation:
-
| Symbol | VIR |
|---|---|
| Price | $30.14 |
| Beta | 0.151 |
| Volume Avg. | 0.83M |
| Market Cap | 4.012B |
| Shares () | - |
| 52 Week Range | 18.05-34.969 |
| 1y Target Est | - |
| DCF Unlevered | VIR DCF -> | |
|---|---|---|
| DCF Levered | VIR LDCF -> | |
| ROE | 60.66% | Strong Buy |
| ROA | 42.39% | Strong Buy |
| Operating Margin | - | |
| Debt / Equity | 25.40% | Neutral |
| P/E | 3.58 | Buy |
| P/B | 1.86 | Strong Buy |
Latest VIR news
About
Download (Excel)Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.